Accumulating evidence suggests that FXR agonism is favorable to liver regeneration and hepatocarcinogenesis [11,12], and contributes to the protection of atherosclerosis and renal diseases [13,14], indicating the systemic effects of FXR activation. Here, NR1H4 is linked to atherosclerosis.